bosentan

This page shows the latest bosentan news and features for those working in and with pharma, biotech and healthcare.

J&J agrees $30bn deal to acquire Actelion

Meanwhile, J&J claims the company's marketed products including its trio of pulmonary artery hypertension (PAH) drugs, including Tracleer (bosentan) - now facing generic competition - as well as follow-up drugs

Latest news

Actelion reports late-stage trial failure as J&J talks continue

Tracleer (bosentan) which has lost patent protection in the US and Europe. .
J&J back in frame to buy Actelion after Sanofi talks break down

Actelion has been through a difficult patch after losing patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), but is on the up with strong growth for follow-up PAH
J&J abandons talks with Actelion as another suitor circles

After a challenging couple of years following the loss of patent protection for pulmonary artery hypertension (PAH) blockbuster Tracleer (bosentan), Actelion is now riding high on the back of strong growth
Resurgent Actelion catches J&J's eye

Actelion's top-selling product Tracleer (bosentan) has already lost patent protection in some markets and saw sales slide 15% in the first nine months of the year to CHF 790m (
Actelion gets EU go-ahead for Uptravi in PAH

Tracleer (bosentan).

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest appointments

J&J's Jane Griffiths named global head of Actelion

At that point it will gain marketed products that include a trio of pulmonary artery hypertension (PAH) drugs - Tracleer (bosentan), Opsumit (macitentan) and Uptravi (selexipag).
New associate director at Packer Forbes

Prior to this role she was a brand lead at pharma company Actelion where she spent several years on the marketing of hypertension treatment Tracleer (bosentan), during which time she worked

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager: Negotiable

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Medical Writer: Salary TBC

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Account Manager: Competitive Salary Offered

Associate Director: £75, 000-90, 000

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Healthcare Communications Account Directors x 2: Salary TBC

Medical (Scientific) Director: £120, 000 benefits

Account Director: Competitive Salary Offered

Business Director: Competitive Salary Offered

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Manager- Healthcare Advertising: Negotiable

Healthcare Advertising Senior Account Manager / AD / Senior AD: Salary TBC

Editorial Manager - MedComms: DOE

Account Executive/ Senior Account Executive: competitive Salary Offfered

Associate Medical Director: Excellent PTO, bonus and 401k package

Experienced Medical Writers: Competitive Salary and Benefits

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Manager- Healthcare Advertising: Negotiable

Account Manager / Senior Account Manager: 35, 000-40, 000

Subscribe to our email news alerts

PMHub

Add my company

Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today: Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham: Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone: Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...